Literature DB >> 1968750

Dominant oncogenes and tumor suppressor genes in the pathogenesis of lung cancer.

J Viallet1, J D Minna.   

Abstract

An understanding of the molecular pathogenesis of lung cancer has evolved from classic cytogenetic studies and the use of restriction fragment length polymorphisms to encompass the definition of specific genetic abnormalities associated with this disease. Activation of the dominant class of oncogenes is frequent, with involvement of the ras and myc families of genes being the best defined. Several examples of inactivation at specific loci exist and have been related to the presence of tumor suppressor genes, most notably the retinoblastoma gene, p53, and a putative gene located on the short arm of chromosome 3. As our understanding of the nature and interactions between these numerous genetic events evolves, new opportunities for early diagnosis, prevention, and treatment will arise.

Entities:  

Mesh:

Year:  1990        PMID: 1968750     DOI: 10.1165/ajrcmb/2.3.225

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  9 in total

Review 1.  Demystified ... oncogenes.

Authors:  Y L Wallis; F Macdonald
Journal:  Mol Pathol       Date:  1999-04

2.  Detection and genotype analysis of human papillomavirus in non-small cell lung cancer patients.

Authors:  Emmanouela Sarchianaki; Stavros P Derdas; Markos Ntaoukakis; Elena Vakonaki; Eleni D Lagoudaki; Ismini Lasithiotaki; Anna Sarchianaki; Anastasios Koutsopoulos; Emmanouil K Symvoulakis; Demetrios A Spandidos; Katerina M Antoniou; George Sourvinos
Journal:  Tumour Biol       Date:  2013-12-06

3.  Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population.

Authors:  Md Shaki Mostaid; Maizbha Uddin Ahmed; Mohammad Safiqul Islam; Muhammad Shahdaat Bin Sayeed; Abul Hasnat
Journal:  Tumour Biol       Date:  2014-07-18

Review 4.  Risks and benefits of retinoids in the chemoprevention of cancer.

Authors:  G de Palo; F Formelli
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

5.  P53 accumulation and proliferating-cell nuclear antigen expression in human lung cancer.

Authors:  T Wiethege; B Voss; K M Müller
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

Authors:  J A Kern; R J Slebos; B Top; S Rodenhuis; D Lager; R A Robinson; D Weiner; D A Schwartz
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

7.  Former poison gas workers and cancer: incidence and inhibition of tumor formation by treatment with biological response modifier N-CWS.

Authors:  M Yamakido; S Ishioka; K Hiyama; A Maeda
Journal:  Environ Health Perspect       Date:  1996-05       Impact factor: 9.031

8.  Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes.

Authors:  E D Papadakis; N Soulitzis; D A Spandidos
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

9.  Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis.

Authors:  Ravshan Burikhanov; Vitaliy M Sviripa; Nikhil Hebbar; Wen Zhang; W John Layton; Adel Hamza; Chang-Guo Zhan; David S Watt; Chunming Liu; Vivek M Rangnekar
Journal:  Nat Chem Biol       Date:  2014-09-14       Impact factor: 15.040

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.